Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > IR news

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on May 15, 2023 6:17pm

71 Views

Post# 35449202

RE:RE:IR news

So would we interpret this that she left on her own accord or Thera got our message and this is the first visible sign of changes?

Mannequin wrote: About time
Trogarzon wrote: Cruella is gone......

Investor Relations

Philippe Dubuc
Senior Vice President and Chief Financial Officer
Phone: +1-438-315-6608
ir@theratech.com